%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
92 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-11-27T11:54:46Z
2024-03-28T16:24:57-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T16:24:57-07:00
application/pdf
Heather
2003-4.jan
uuid:f59777ac-1dd1-11b2-0a00-ef0927bd7700
uuid:f59777af-1dd1-11b2-0a00-900000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 10 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
106 0 obj
[110 0 R]
endobj
107 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(6.)-875.1 (A)74 (vila JJ, L)54.8 (ympany P)91.7 (A, Pantelidis P)110.7 (,)-0.1 ( )17.7 (W)79.9 (elsh KI, Black CM, du Bois)]TJ
1.675 -1.25 Td
(RM. Fibronectin gene polymorphism associated with fibrosing)Tj
0 -1.25 TD
[(alveolitis in systemic sclerosis. )54.8 (Am J Respir Cell Mol Biol)]TJ
0 Tc 0 Tw T*
(1999;20:106-12.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Dinarello CA. Biologic basis for interleukin-1 in disease. Blood)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(1996;87:2095-147.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Nicklin MJ, )17.7 (W)79.9 (eith )54.8 (A, Duf)17.7 (f GW)91.7 (. )54.8 (A)-220.1 (physical map of the region)]TJ
1.675 -1.25 Td
(encompassing the human interleukin-1 alpha, interleukin-1 beta,)Tj
T*
(and interleukin-1 receptor antagonist genes. Genomics)Tj
0 Tc 0 Tw T*
(1994;19:382-4.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (McDowell )17.7 (TL, Symons JA, Ploski R, Forre O, Duf)17.7 (f GW)91.7 (. )54.8 (A)-220.1 (genetic)]TJ
1.675 -1.25 Td
(association between juvenile rheumatoid arthritis and a novel )Tj
0 Tw T*
(interleukin-1)Tj
/T1_1 1 Tf
0 Tc [0.1 (\002)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 6.0704 0 Td
[(polymorphism. )54.8 (Arthritis Rheum 1995;38:221-8.)]TJ
-8.2454 -1.25 Td
[(10.)-875.1 (Hulkkonen J, Laippala P)110.7 (, Hurme M. )54.8 (A)-220.1 (rare allele combination of)]TJ
2.175 -1.25 Td
(the interleukin-1 gene complex is associated with high interleukin-1)Tj
T*
(beta plasma levels in healthy individuals. Eur Cytokine Netw)Tj
0 Tw T*
[(2000;1)36.8 (1:251-5.)]TJ
0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Kawaguchi )36.8 (Y)128.9 (. IL-1 alpha gene expression and protein production)]TJ
2.1381 -1.25 Td
(by fibroblasts from patients with systemic sclerosis. Clin Exp)Tj
T*
(Immunol 1994;97:445-50.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Kantor )17.7 (TV)128.8 (, Friber)17.7 (g D, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (, Buckingham RB, )17.7 (Whiteside)]TJ
2.175 -1.25 Td
(TL. Cytokine production and serum levels in systemic sclerosis.)Tj
T*
(Clin Immunol Immunopathol 1992;65:278-85.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Preliminary criteria for the classification of systemic sclerosis )]TJ
2.175 -1.25 Td
(\(scleroderma\). Subcommittee for Scleroderma Criteria of the)Tj
T*
[(American Rheumatism )54.8 (Association Diagnostic and )17.7 (Therapeutic)]TJ
T*
[(Criteria Committee. )54.8 (Arthritis Rheum 1980;23:581-90.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Miller SA, Dykes DD, Polesky HF)79.7 (. )54.8 (A)-220.1 (simple salting out procedure)]TJ
2.175 -1.25 Td
[(for extracting DNA)-220.2 (from human nucleated cells. Nucl )54.8 (Acids Res)]TJ
0 Tc 0 Tw T*
(1988;16:1215-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Bunce M, O\325Neill CM, Barnardo MC, et al. Phototyping: )]TJ
2.175 -1.25 Td
[(comprehensive DNA)-220.2 (typing for HLA-A, B, C, DRB3, DRB4,)]TJ
T*
(DRB5 and DQB1 by PCR with 144 primer mixes utilising)Tj
T*
[(sequence-specific primers \(PCR-SSP\). )17.7 (T)35 (issue )54.8 (Antigens)]TJ
0 Tc 0 Tw T*
(1995;46:355-67.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Postlethwaite )54.8 (AE, Raghow R, Stricklin GP)110.7 (, Poppleton H, Seyer JM,)]TJ
2.175 -1.25 Td
[(Kang )54.8 (AH. Modulation of fibroblast functions by interleukin 1:)]TJ
T*
(increased steady-state accumulation of type I procollagen)Tj
T*
(messenger RNAs and stimulation of other functions but not )Tj
T*
(chemotaxis by human recombinant interleukin 1 alpha and beta. )Tj
T*
[(J Cell Biol 1988;106:31)36.8 (1-8.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Riquet FB, Lai )17.7 (WF)79.7 (, Birkhead JR, Suen LF)79.7 (, Karsenty G, Goldring)]TJ
2.175 -1.25 Td
(MB. Suppression of type I collagen gene expression by)Tj
T*
(prostaglandins in fibroblasts is mediated at the transcription level.)Tj
T*
(Mol Med 2000;6:705-19.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Rezzonico R, Bur)17.7 (ger D, Dayer JM. Direct contact between )17.7 (T)]TJ
2.175 -1.25 Td
(lymphocytes and human dermal fibroblasts or synoviocytes )Tj
T*
(down-regulates types I and III collagen production via )Tj
T*
(cell-associated cytokines. J Biol Chem 1998;273:18720-8.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Kolb M, Mar)17.7 (getts PJ, )54.8 (Anthony DC, Pitossi F)79.7 (, Gauldie J. )17.7 (T)35 (ransient)]TJ
2.175 -1.25 Td
(expression of IL-1\247 induces acute lung injury and chronic repair)Tj
T*
(leading to pulmonary fibrosis. J Clin Invest 2001;107:1529-36.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Lonnemann G, Engler)19.7 (-Blum G, M\237ller GA, Koch KM, Dinarello)]TJ
2.175 -1.25 Td
(CA. Cytokines in human renal interstitial fibrosis. II. Intrinsic )Tj
T*
(interleukin \(IL\)-1 synthesis and IL-1-dependent production of IL-6)Tj
T*
(and IL-8 by cultured kidney fibroblasts. Kidney Int )Tj
0 Tc 0 Tw T*
(1995;47:845-54.)Tj
-0.00011 Tc 0.02499 Tw 30.825 69.9839 Td
[(21.)-875.1 (Kawaguchi )36.8 (Y)128.9 (, Hara M, )17.7 (W)39.8 (right )17.7 (TM. Endogenous IL-1)]TJ
/T1_1 1 Tf
0 Tc 0 Tw 23.7172 0 Td
(\002)Tj
/T1_0 1 Tf
-0.0002 Tc 0.9059 0 Td
(from)Tj
-0.00011 Tc 0.02499 Tw -22.4481 -1.25 Td
(systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin)Tj
T*
(Invest 1999;103:1253-60.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Y)99.8 (amamoto )17.7 (T)74 (, Sawada )36.8 (Y)128.9 (, Katayama I, Nishioka K. Increased)]TJ
2.175 -1.25 Td
(production of nitric oxide stimulated by interleukin-1\247 in peripheral\
)Tj
T*
(blood mononuclear cells in patients with systemic sclerosis. Br )Tj
T*
[(J Rheumatol 1998;37:1)36.8 (123-5.)]TJ
-2.175 -1.25 Td
[(23.)-875.1 (Shirodaria S, Smith J, McKay IJ, Kennett CN, Hughes FJ.)]TJ
2.175 -1.25 Td
[(Polymorphisms in the IL-1A)-220.2 (gene are correlated with levels of)]TJ
0 Tw T*
(interleukin-1)Tj
/T1_1 1 Tf
0 Tc (\002)Tj
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 6.0705 0 Td
(protein in gingival crevicular fluid of teeth with)Tj
-6.0704 -1.25 Td
(severe periodontal disease. J Dent Res 2000;79:1864-9.)Tj
-2.175 -1.25 Td
[(24.)-875.1 (Kawaguchi )36.8 (Y)128.9 (,)-0.1 ( )17.7 (T)69.9 (ochimoto )54.8 (A, Ichikawa )54.8 (A, et al. )54.8 (Association of IL1A)]TJ
2.175 -1.25 Td
(gene polymorphisms with susceptibility to and severity of systemic)Tj
T*
[(sclerosis in the Japanese population. )54.8 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(2003;48:186-92.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875.1 (Kornman KS, Crane )54.8 (A, )17.7 (W)79.9 (ang HY)128.8 (, et al. )17.7 (The interleukin-1 genotype)]TJ
2.175 -1.25 Td
(as a severity factor in adult periodontal disease. J Clin Periodontol)Tj
0 Tc 0 Tw T*
(1997;24:72-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Grimaldi LM, Casadei )17.7 (VM, Ferri C, et al. )54.8 (Association of )]TJ
2.175 -1.25 Td
[(early-onset )54.8 (Alzheimer)-37 (\325)55.1 (s disease with an interleukin-1 alpha gene)]TJ
T*
[(polymorphism. )54.9 (Ann Neurol 2000;47:361-5.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (T)69.9 (ountas NA, Casini-Raggi )17.7 (V)128.9 (,)-0.1 ( )36.8 (Y)99.8 (ang H, et al. Functional and ethnic)]TJ
2.175 -1.25 Td
(association of allele 2 of the interleukin-1 receptor antagonist gene)Tj
T*
[(in ulcerative colitis. Gastroenterology 1999;1)36.8 (17:806-13.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Hutyrova B, Pantelidis P)110.7 (, Dr\207bek J, et al. Interleukin-1 gene cluster)]TJ
2.175 -1.25 Td
(polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis.)Tj
T*
(Am J Respir Crit Care Med 2002;165:148-51.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Moller DR. Involvement of )17.7 (T)-257.1 (cells and alterations in )17.7 (T)-257.1 (cell )]TJ
2.175 -1.25 Td
(receptors in sarcoidosis. Semin Respir Infect 1998;13:174-83.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (V)110.8 (alentini G, Baroni )54.8 (A, Esposito K, et al. Peripheral blood )17.7 (T)]TJ
2.175 -1.25 Td
[(lymphocytes from systemic sclerosis patients show both )17.7 (Th1 and)]TJ
T*
(Th2 activation. J Clin Immunol 2001;21:210-7.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (T)69.9 (suji-Y)99.8 (amada J, Nakazawa M, Minami M, Sasaki )17.7 (T)74 (. Increased)]TJ
2.175 -1.25 Td
(frequency of interleukin 4 producing CD4+ and CD8+ cells in)Tj
T*
(peripheral blood from patients with systemic sclerosis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;28:1252-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875.1 (Fujii H, Hasegawa M, )17.7 (T)69.9 (akehara K, Mukaida )54.8 (A, Sato S. )54.8 (Abnormal)]TJ
2.175 -1.25 Td
(expression of intracellular cytokines and chemokine receptors in)Tj
T*
[(peripheral blood )17.7 (T)-257.1 (lymphocytes from patients with systemic )]TJ
T*
(sclerosis. Clin Exp Immunol 2002;130:548-56.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (Mavalia C, Scaletti C, Romagnani P)110.7 (, et al. )17.7 (T)69.9 (ype 2 helper )17.7 (T)91.9 (-cell)]TJ
2.175 -1.25 Td
[(predominance and high CD30 expression in systemic sclerosis. )54.8 (Am)]TJ
T*
(J Pathol 1997;151:1751-8.)Tj
-2.175 -1.25 Td
[(34.)-875.1 (Huber M, Beuscher HU, Rohwer P)110.7 (, Kurrle R, R\232llinghof)17.7 (f M,)]TJ
2.175 -1.25 Td
[(Lohof)17.7 (f M. Costimulation via )17.7 (TCR and IL-1 receptor reveals a)]TJ
T*
(novel IL-1)Tj
/T1_1 1 Tf
0 Tc 0 Tw [-0.2 (\002)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (-mediated autocrine pathway of )17.7 (Th2 cell proliferation. )]TJ
0.0001 -1.25 Td
(J Immunol 1998;160:4242-7.)Tj
-2.175 -1.25 Td
[(35.)-875.1 (Cardon LR, Palmer LJ. Population stratification and spurious allelic)]TJ
2.175 -1.25 Td
(association. Lancet 2003;361:598-604.)Tj
-2.175 -1.25 Td
[(36.)-875.1 (Louie LG, )17.7 (W)79.9 (allenstein E, Direskeneli GS, et al. Report of the)]TJ
2.175 -1.25 Td
(Anthropology Group from the Cytokine Polymorphism)Tj
T*
(Component, 13th IHWC. In: Hansen JA, Dupont B, editors. HLA)Tj
T*
(2002. Immunology of the human MHC. vol. 2. Seattle: IHWG)Tj
T*
(Press; 2003 \(in press\).)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:1)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(84)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
16 0 obj
<>stream
8;Z\5!ESM?%.jENkj*UcD+RLX,o[O^n(!@+QIM%.=`M4:NkZ<@+"r!=nb=XIlPAr]
5G,.>WA`F>ouM;m5^I7'f9,#oNhg_Oh+nU'<09?ro'&'30k'/cX3=oXMkaP!%=2TH
0I?*)Te3g2200i&hA0fj@t7Vk1p67D"H(l(kf\X!#i]=Y4nM*]9ft\`W%n+?;_=Cc
H86:OVi;Z+(JY0(/B#FTGZ#ifTtgX8@hkaXbeW^
0Wr7)oH&INZ/(:Q>9;oRT#kp)
%OG29rJeV%WWWqsPF5?pPaC%_Q*J!Q3>96R_fDn^n=(%00+150X~>
endstream
endobj
20 0 obj
[/Indexed/DeviceRGB 255 19 0 R]
endobj
19 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
48 0 obj
<>
endobj
42 0 obj
<>
endobj
40 0 obj
<>
endobj
83 0 obj
<>
endobj
97 0 obj
<>
endobj
41 0 obj
<>
endobj
75 0 obj
<>stream
HiPSYC0=d^nS("ҢV,bl݈,iIXa D FPqWafzR{K_fΗ/S_ι8fl8nwn0'^KOx:b.3b v\t9qܘu1Eېg&s;jn}'
+q9^4,aV'Yygkޫ$
yLT, ̮(M('%P+fD<1Oi~13qDĉ0o ~P"M1>;uB7ԉ3D~_pLqll1̰(#La700:H, &G| .Ǎ4FsFxfgt'K89&&(ojtEn1f'柛w-X.^]B-0ȳtT[ZZ߷9`BӶK]m7efC1\+Fmb";;s;TQf
UbO'oF}W_aN^Q3>KCə!h%2ER
gFo8v'lQ\F
_}/+k+rҼx쌤F%sUTqn\C؟p5@:GP٩vvfh3w:SWBi4Jŏ@ޏ:1\&EUMG˛Wߨhlr0LbId7o`WjYG ͐+2iWke}:Gq5z,, uЯKZ^kR٨jt<٨J)*/sÂ<|4Q
5&1gNqϞ|?f \i'XY"qD ?fd̥iwyYX.؏ecw&O`!
N W1:aAmt